Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

Company Growth (employees)
Type
Public
HQ
Hayward, US
Size (employees)
16 (est)
Aradigm is headquartered in Hayward, US

Key People at Aradigm

Igor Gonda

Igor Gonda

President & Chief Executive Officer
Nancy Pecota

Nancy Pecota

Chief Financial Officer

Aradigm Office Locations

Aradigm has an office in Hayward
Hayward, US (HQ)
3929 Point Eden Way

Aradigm Data and Metrics

Aradigm Financial Metrics

Aradigm's revenue was reported to be $1.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

1.7 m

EBIT (Q1, 2017)

(2.8 m)

Market capitalization (22-Aug-2017)

18.7 m

Cash (31-Mar-2017)

17.2 m
Aradigm's current market capitalization is $18.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

9.7 m33.6 m23.4 m195 k

Revenue growth, %

245%(30%)(99%)

R&D expense

24.4 m

General and administrative expense

5.8 m

Operating expense total

30.2 m

EBIT

(19.9 m)(3.9 m)(17.2 m)(30 m)

EBIT margin, %

(205%)(11%)(73%)(15396%)

Interest expense

1.6 m288 k288 k2.4 m

Interest income

6 k17 k29 k88 k

Net Income

(21.6 m)4.7 m(17.2 m)(32.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

12.2 m6.6 m8.8 m10 m4.7 m6 k14 k50 k1.7 m

R&D expense

11.7 m6 m8.4 m9.8 m8.9 m6.5 m6.2 m5.8 m2.8 m

General and administrative expense

1.9 m1.4 m1.5 m1.3 m1.3 m1.6 m1.4 m1.5 m1.7 m

Operating expense total

13.6 m7.5 m9.9 m11.1 m10.2 m8.1 m7.6 m7.3 m4.5 m

EBIT

(1.3 m)(877 k)(1.1 m)(1.1 m)(5.5 m)(8.1 m)(7.6 m)(7.2 m)(2.8 m)

EBIT margin, %

(11%)(13%)(13%)(11%)(118%)(134833%)(54336%)(14492%)(163%)

Interest expense

288 k577 k898 k953 k

Interest income

1 k5 k8 k7 k7 k10 k26 k34 k28 k

Net Income

(1.4 m)(914 k)(1.1 m)(5.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

48.1 m48 m31.5 m22.6 m

Accounts Receivable

499.1 m

Current Assets

49.7 m50.5 m35.2 m24.8 m

PP&E

400 k502 k299 k253 k

Total Assets

50.4 m54 m35.6 m25.1 m

Accounts Payable

619 k2.7 m1.8 m711 k

Current Liabilities

7.3 m6.8 m7.5 m5.8 m

Total Liabilities

24.1 m

Retained Earnings

(392.9 m)(388.3 m)(405.5 m)(438.4 m)

Total Equity

33.7 m39.1 m23.1 m987 k

Financial Leverage

1.5 x1.4 x1.5 x25.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

50.3 m48.5 m48.6 m49 m40 m22.4 m31.2 m28.5 m17.2 m

Current Assets

52.6 m49.8 m50.8 m50.9 m41.6 m26.5 m35.7 m32 m19.7 m

PP&E

539 k582 k416 k353 k325 k310 k282 k278 k225 k

Total Assets

56.1 m53.4 m54.1 m54.1 m44.8 m26.8 m36 m32.3 m19.9 m

Accounts Payable

4 m1.4 m2 m3 m1.9 m2.5 m1.2 m956 k532 k

Current Liabilities

7.4 m5.5 m8 m8.7 m7.5 m6.6 m5.2 m6.1 m13.3 m

Retained Earnings

(386.5 m)(387.4 m)(389.4 m)(390.6 m)(396.1 m)(413.6 m)(422.3 m)(430.5 m)(448.1 m)

Total Equity

40.5 m39.7 m38.1 m37.4 m32.1 m15.3 m15.5 m8.4 m(7.7 m)

Financial Leverage

1.4 x1.3 x1.4 x1.4 x1.4 x1.8 x2.3 x3.8 x-2.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.6 m)4.7 m(17.2 m)(32.9 m)

Depreciation and Amortization

370 k310 k203 k121 k

Accounts Payable

289 k2.1 m(917 k)(1.1 m)

Cash From Operating Activities

264 k107 k(16.7 m)(28.5 m)

Capital Expenditures

(43 k)(412 k)(412 k)(75 k)

Cash From Investing Activities

131 k(412 k)(412 k)(1.1 m)

Cash From Financing Activities

40.3 m164 k175 k20.7 m

Interest Paid

1 m

Free Cash Flow

307 k519 k(16.3 m)(28.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.4 m)(914 k)(1.1 m)(5.5 m)

Accounts Payable

4 m1.4 m2 m3 m1.9 m2.5 m1.2 m956 k532 k
USDY, 2017

Revenue/Employee

105.8 k

Financial Leverage

-2.6 x

Aradigm Operating Metrics

FY, 2014FY, 2015FY, 2016

Patents Pending

352749

Patents Issued

828280

    Aradigm Market Value History

    Traffic Overview of Aradigm

    Aradigm Company Life and Culture

    You may also be interested in